Review Article

Advances in metabolic engineering of Corynebacterium glutamicum to produce high-value active ingredients for food, feed, human health, and well-being

Sabrina Wolf1, Judith Becker1, Yota Tsuge2, Hideo Kawaguchi3, Akihiko Kondo3,4,5, Jan Marienhagen6,7,8, Michael Bott6,8, Volker F. Wendisch9 and Christoph Wittmann1

1Institute of Systems Biotechnology, Saarland University, Saarbrücken, Germany; 2Institute for Frontier Science Initiative, Kanazawa University, Japan; 3Graduate School of Science, Technology and Innovation, Kobe University, Japan; 4Graduate School of Engineering, Kobe University, Japan; 5Biomass Engineering Research Division, RIKEN, Yokohama, Japan; 6Institute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich, Germany; 7Institute of Biotechnology, RWTH Aachen University, Aachen, Germany; 8The Bioeconomy Science Center (BioSC), Forschungszentrum Jülich, Germany; 9Genetics of Prokaryotes, Biology & CeBiTec, Bielefeld University, Germany

Correspondence: Christoph Wittmann (christoph.wittmann@uni-saarland.de)

The soil microbe Corynebacterium glutamicum is a leading workhorse in industrial biotechnology and has become famous for its power to synthesise amino acids and a range of bulk chemicals at high titre and yield. The product portfolio of the microbe is continuously expanding. Moreover, metabolically engineered strains of C. glutamicum produce more than 30 high value active ingredients, including signature molecules of raspberry, savoury, and orange flavours, sun blockers, anti-ageing sugars, and polymers for regenerative medicine. Herein, we highlight recent advances in engineering of the microbe into novel cell factories that overproduce these precious molecules from pioneering proofs-of-concept up to industrial productivity.

Introduction

Corynebacterium glutamicum is a Gram-positive, non-spore-forming facultative anaerobic bacterium with a moderate to high GC content belonging to the phylum of actinobacteria [1]. The microbe is traditionally used to manufacture amino acids through fermentation [2], including the premium products L-glutamate [3,4], L-lysine [5–7], L-arginine [8], and L-tryptophan [9]. Remarkable efforts in metabolic engineering have widened the product portfolio of C. glutamicum to over 70 different compounds [10], including bulk biofuels [11,12], and bulk chemicals such as lactate [13,14], succinate [13,15,16], cis,cis-muconate [17], cadaverine (diaminopentane) [18–21], aminovalerate [22], glutarate [22–25], and 3-amino-4-hydroxybenzoate [26]. The lessons learned about C. glutamicum have revealed: (i) the microbe grows quickly to high cell densities, shows no autolysis, and can be easily propagated to a large scale (>750 cubic meters). (ii) C. glutamicum produces no endotoxins, does not undergo phage lysis, and is generally recognised as safe (GRAS), allowing the synthesis of a range of commercial products granted GRAS status by the United States Food and Drug Administration for the food and pharmaceutical industries. (iii) It consumes various carbon substrates and can simultaneously utilise substrate mixtures [27–29], favouring the application of hydrolysed lignocellulosic biomass and even waste materials as eco-friendly feedstock for fermentation [11,17,27,30]. (iv) C. glutamicum shows a high tolerance to toxic compounds and other forms of stress [31] due to its robust cell wall, composed of a thick glycocalyx core and, in some strains, a crystalline surface S-layer [32–34].
Table 1 Fermentative production of high-value branched chain and non-proteinogenic amino acids using metabolically engineered C. glutamicum

| Product       | Genotype                                                                 | Substrate       | Titre [g.l⁻¹] | Productivity [g.l⁻¹ h⁻¹] | Yield [g g⁻¹] | Reference |
|---------------|----------------------------------------------------------------------------|-----------------|---------------|------------------------|--------------|-----------|
| L-Valine      | R (JCM 18229)ΔldhA Δppc Δpta ΔackA ΔactA ΔsavAΔNAD⁺C⁷⁻ΔgapA + + Δpyk + ΔptkA + pCRB-ΔBN⁺ΔE-C⁷⁻ + pCRB-DLD | Glucose         | 150.0         | 6.3                    | 0.57         | [63]      |
| L-Leucine     | ML1-9ΔilvA ΔalaT Δldh ΔltbR ΔpanBC leuAR | Glucose         | 38.1          | 0.8                    | 0.30         | [69]      |
| L-Isoleucine  | IWJ001ΔilvA ΔalaT Δldh + pDXW-8-grd-fbp-pgl | Glucose         | 29.0          | 0.4                    | 0.14         | [70]      |
| γ-Aminobutyrate | G01 gad plk ΔargB ΔproB ΔdapA | Glucose         | 70.6          | 1.0 n.s.²      |              | [78]      |

²ΔNAD⁺,C⁷⁻, feedback-resistant mutant ilvN (G165E); ΔNAD⁺, NAD-prefering mutant ilvC (S34G, L48E, R49F).
³ML1-9, classical mutant from screening against L-leucine analogues, leuAR, feedback resistant mutant leuA (R529H, G532D, L535V).
⁴IWJ001, industrial L-isoleucine producer.

Supported by a well-established understanding of its genomic repertoire [31,33], powerful engineering tools and techniques have been developed to systematically analyse and modify C. glutamicum. Systems-wide (multi)omics approaches [35–37] have allowed experimental studies of the microbe at transcriptome, proteome, metabolome, and fluxome levels [10,38] and their functional interactions [37,39], while computational simulations have explored the metabolic pathway capabilities and optimum flux states, and guiding strain engineering [40–42]. For tailored gene expression, a wide range of low- and high-copy number shuttle vectors, promoters, and control elements, selection markers, and reporter genes are available [33,43–48]. These techniques have, inter alia, enabled the construction of genome reduced strains such as C. glutamicum C1*, CR099, and their derivatives, which have emerged as a valuable chassis for basic research and industrial development [49,50]. Other interesting developments have involved the use of biosensors to translate intracellular product levels into optical outputs to screen for superior phenotypes [51–53]. Evolutionary approaches have provided strains with elevated tolerance to industrial processing environments, including high temperatures [54] and oxidative stress [55], which are important from a production standpoint. Recent efforts have also enabled the use of C. glutamicum in anodic electro-fermentations [56].

Herein, we review recent achievements in the metabolic engineering of C. glutamicum for the production of high-value molecules to be used in medical, pharmaceutical, and nutraceutical applications, including amino acids, (poly)phenols, terpenoids, extremolytes, and medical polymers (Figure 1), extending from valuable proof-of-concept studies up industrial processes (Tables 1-4).

Pharmaceutical amino acids

Amino acids are essential for health and play an important role as food additives, medically active ingredients, and building blocks for pharmaceuticals [57]. In 2020, the global amino acid market reached a volume of 9.8 million tons per year, which is estimated at US$ 21 Billion and is projected to reach US$ 27 Billion in 2027. The top low-price bulk amino acids for use in food and feed are L-lysine [6], L-glutamate [3], L-tryptophan [9], and L-methionine [41,58]. In addition, C. glutamicum has been successfully engineered to produce amino acids with a higher value, mainly for pharmaceutical and medical applications, including branched chain and non-proteinogenic derivatives [59] (Table 1).
Table 2 Fermentative production of high value (poly)phenols, and related natural products using metabolically engineered C. glutamicum

| Product                          | Genotype                  | Substrate/ Precursor | Titre [mg.l\(^{-1}\)] | Reference |
|---------------------------------|---------------------------|-----------------------|------------------------|-----------|
| Cyanidin 3-O-glucoside (C3G)    | + pZM1.eftuSUMO-3GT-eftuANS | Catechin              | 40                     | [88]      |
| Salidroside                     | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-C5 mufasO\(_{BCD1}\) | Tyrosol               | 9000                   | [98]      |
| Naringenin                      | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | p-Coumaric acid       | 37                     | [96]      |
| Dihydrokaempferol               | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | p-Coumaric acid       | 20                     | [96]      |
| Kaempferol                      | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | p-Coumaric acid       | 23                     | [96]      |
| Eriodictyol                     | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | Caffeic acid          | 12                     | [96]      |
| Dihydroquercetin                | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | Caffeic acid          | 7                      | [96]      |
| Quercetin                       | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | Caffeic acid          | 10                     | [96]      |
| Resveratrol                     | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^3\)             | p-Coumaric acid       | 158                    | [96,97]   |
| Mono-O-methylated pinostilbene  | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)             | p-Coumaric acid       | 3                      | [96]      |
| Di-O-methylated pterostilbene   | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)             | p-Coumaric acid       | 42                     | [96]      |
| Pinosylvin                      | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro3+pMK2.stau4.4cI\(_{bc}\) | Cinnamic acid        | 121                    | [97]      |
| Piceatannol                     | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro3+pMK2.stau4.4cI\(_{bc}\) | Caffeic acid        | 56                     | [97]      |
| Noreugenin                      | **MB001(DE3)**            |                       |                        |           |
|                                 | DelAro\(^4\)-4cI\(_{bc}\) | Glucose               | 53                     | [94]      |

Continued over
The branched chain amino acids L-valine, L-leucine, and L-isoleucine

The amino acid L-valine is an important precursor of antibiotics [60,61] and herbicides [62]. Engineered *C. glutamicum* strains accumulate l-valine to a titre of 227 g L\(^{-1}\) under oxygen deprivation within only 48 h [63]. Although the reported value was corrected for volume increase and dilution effects during fed-batch production and the effective concentrations reached during the process were approximately 2-fold lower [64], the achieved performance is undoubtedly impressive (Table 1). Producing strains are characterised by enhanced biosynthesis controlled by acetoxyacid synthase (AHAS, *ilvNGE*), disrupted routes to undesired by-products (lactate, succinate), an amplified glycolytic pathway, and optimised redox balancing using an NAD-preferring mutant of acetohydroxyacid isomeroreductase (AHAIR, *ilvC*\(^{TM}\)) during production [57,60]. Transcriptomics and proteomics furthermore have revealed that up-regulation of the branched chain amino acid exporter genes *brnFE* promotes l-valine secretion capability [65], displaying a promising target for future metabolic engineering interventions [66].
Furthermore, it was also possible to generate l-leucine-producing strains of *C. glutamicum* characterised by the overexpression of feedback-resistant variants of the central enzyme 2-isopropylmalate synthase (IPMS, leuA) and a fine-tuned redistribution of precursor supply [57,67]. For example, overexpression of a mutated leuA variant (amino acid exchanges R529H, G532D) was combined with deletion of *lbtR* (*leuBCD*), PTS-independent glucose uptake via *iolR* deletion, and an attenuated flux through citrate synthase (*gltA*), strategies yielding a strain that achieved 24 g.l⁻¹ l-leucine within 72 h in a fed-batch process [68]. The best performance was achieved by metabolic engineering of a classically generated mutant strain (ML1-9), obtained by screening of structural l-leucine analogues [69]. The producer overexpressed a feedback resistant leuA gene variant with three amino acid exchanges (R529H, G532D, and L535V) but lacked *lbtR* to increase expression of *leuBCD* and lacked *alaT, panBC*, and *ilvA* to increase precursor
availability (Table 1). It achieved a titre of 38.1 g.L\(^{-1}\) and l-isoleucine production, which using this strain, could achieve quantities up to industrial scales (150 m\(^3\)) [69].

Interesting engineering strategies transformed deregulated l-lysine producers into l-isoleucine producers. As an example, the expression of several gene copies of hom, encoding a feedback-resistant l-homoserine dehydrogenase, and ilvA, encoding a deregulated l-threonine dehydratase, yielded 13 g.L\(^{-1}\) l-isoleucine [68]. Metabolic engineering of the industrial l-isoleucine producing strain IWJ001 channelled carbon into the pentose phosphate pathway for enhanced NADPH supply and increased the production up to 29 g.L\(^{-1}\) l-isoleucine [70].

### The neurotransmitter \(\gamma\)-aminobutyrate

\(\gamma\)-Aminobutyrate (GABA) is a non-proteinogenic amino acid of four carbons, which exhibits recognised blood pressure lowering activity and is used in pharmaceuticals and functional foods [71–73]. Biochemically, it is derived from l-glutamate via pyridoxal phosphate (PLP) dependent l-glutamate decarboxylase (GAD), suggesting \(C.\ glutamicum\) with its known l-glutamate production potential as promising host, although the microbe is also able to use GABA as sole carbon and nitrogen source [74]. Heterologous expression of l-glutamate decarboxylase (gadAB) from \(E.\ coli\) in wild-type \(C.\ glutamicum\) ATCC 13032 yielded a producer which accumulated 8 g.L\(^{-1}\) GABA within 96 h [72]. Subsequently, the impact of GABA catabolism and re-uptake was assessed, leading to the discovery of the GABA specific transport protein GabP [75]. A gabP deletion mutant showed 12.5% higher GABA production than the parental strain. Expression of a mutant l-glutamate decarboxylase with a broader pH optimum under the control of a strong synthetic promoter (H36) then leveraged production to 38.1 g.L\(^{-1}\) [76]. Subsequently, additional expression of xyla from \(E.\ coli\) provided strains that simultaneously utilised glucose and xylose and accumulated GABA up to a titre of 35.5 g.L\(^{-1}\), using an empty fruit bunch biosugar solution as a carbon source [77]. An elegant approach decoupled GABA production from the requirement for external PLP, an otherwise expensive ingredient [78]. The cofactor was simply regenerated by expressing PLP kinase from \(Lactobacillus\ plantarum\) GB 01-21. Combined with heterologous expression of GAD from the same donor and disruption of pathways to relevant by-products (l-arginine, l-proline, l-lysine), this strategy has yielded the best GABA producer to date (Table 1). The engineered \(C.\ glutamicum\) strain achieved 70.6 g.L\(^{-1}\) GABA [78]. An alternative pathway to GABA was established in putrescine-producing \(C.\ glutamicum\) by expressing the \(E.\ coli\) genes putrescine transaminase (patA) and \(\gamma\)-aminobutyraldehyde dehydrogenase (patD), which enabled a titre of 5.3 g.L\(^{-1}\) [79].

### The microbial sunscreen shinorine

Shinorine (mycosporine-glycine-serine) belongs to the group of mycosporine and mycosporine-like amino acids which are small, water soluble compounds with a cyclohexenone or cyclohexenimine scaffold. Naturally, these molecules are synthesised by cyanobacteria, fungi, and in micro- and macroalgae. They efficiently absorb UVA and UVB light, capture reactive oxygen species (ROS), protect macromolecules and cells and act as microbial sunscreens, which are promising for skin care cosmetics [80,81]. The biosynthesis of shinorine requires the intermediate sedoheptulose 7-phosphate which is converted to dimethyl 4-deoxygadusol and 4-deoxygadusol, and is followed by the addition of a glycine to form mycosporine-glycine and the final attachment of l-serine, involving a non-ribosomal peptide synthetase (NRPS) homologue [81]. Heterologous shinorine production in \(C.\ glutamicum\) therefore involves a modification of the pentose phosphate pathway to increase sedoheptulose 7-phosphate supply, specifically, the deletion of transaldolase (tal) and the overexpression of 6-phosphogluconate dehydrogenase (gnd) [81]. Plasmid-based expression of the shinorine operon genes (amir4256-amir4259) from \(Actinosynnema\ mirum\) then yielded the compound at a titre of 19 mg.L\(^{-1}\) [81].

### Plant polyphenols

Plant polyphenols are naturally found in fruits, vegetables, cereals, and beverages [82–84], and comprise several thousand compounds [83,85]. Studies suggest that long-term consumption of a diet rich in plant polyphenols offers protection against different cancers, cardiovascular diseases, diabetes, osteoporosis, and neurodegenerative diseases [82–84], opening opportunities for the application of polyphenols as pharmaceuticals, nutraceuticals, and food additives [86]. Microbial production normally outcompetes traditional extraction from plant tissues, given drawbacks such as low yield, seasonal variation, and product instability, associated to the latter [87,88]. In comparison with other tested hosts, \(C.\ glutamicum\) shows superior natural robustness against toxic aromatics [89], making it a promising host for the production of aromatic molecules [88,90,91] (Table 2). This trait can be partially attributed to the complex catabolic network for aromatic compounds in \(C.\ glutamicum\), which needs to be modified prior to establishing polyphenol biosynthesis in this organism [91,92]. Furthermore, because plant polyphenol synthesis requires large
amounts of malonyl-CoA [93], the central metabolism of *C. glutamicum* was extensively re-engineered to meet the increased demands for this metabolite [94,95]. Additional challenges arose from the fact that implementation of pathways for polyphenols synthesis requires the functional expression of plant-derived enzymes in bacteria, which are often characterised by incomplete posttranslational modification or formation of inclusion bodies due to incorrect protein folding [82–84,86,88,90,96,97].

**Flavonoids**

Flavonoids are characterised by two benzene rings linked to a pyrane or pyrone ring, and derivatives result from substitution with hydroxyl groups, including alkylated and/or glycosylated moieties [88,96]. Recently, several flavonoids were successfully produced in recombinant *C. glutamicum* [88,96,97] (Table 2). For example, the production of the anthocyanin cyanidin 3-O-glucoside from catechin was achieved by co-expression of anthocyanidin synthase from *Petunia hybrida* and 3-O-glucosyltransferase from *Arabidopsis thaliana* enabling a production titre of 40 mg l⁻¹, when UDP-glucose was supplied [88].

**Stilbenoids**

Stilbenoids are hydroxylated diacylethenes, characterised by an ethylene moiety with one phenyl group on each side. Most stilbenoids are synthesised in plants as response to infection or injury. Studies suggest that resveratrol, the most prominent and commercially relevant stilbenoid, mediates health-promoting effects against a range of different cancers and supports the immune system and antioxidative defence mechanisms [90]. The first resveratrol producing *C. glutamicum* variants carried genes for 4-coumaroyl-CoA ligase (4CL) obtained from *Petroselinum crispum* and stilbene synthase (STS) from *Arachis hypogaea* and allowed an accumulation of up to 158 mg l⁻¹ of resveratrol when supplemented with p-coumaric acid [96,97] (Table 2). Alternatively, a synthetic reverse β-oxidative pathway was established in *C. glutamicum*, which allowed the synthesis of resveratrol from inexpensive 4-hydroxybenzoate without supplementation of the much more costly p-coumaric acid [98]. Furthermore, resveratrol can be directly produced from glucose without addition of any precursor molecules. However, in addition to the heterologous expression of genes conferring 4CL and STS activity, these strains required a tyrosine ammonia-lyase activity for the non-oxidative elimination of the primary amino group of L-tyrosine provided by microbial metabolism [97,99].

**Plant phenols**

**Salidroside, active against neurodegenerative diseases**

A success story in bacterial plant phenol synthesis is the production of salidroside, a compound found in many raspberry species and active against the pathological processes of neurodegenerative diseases [84,86]. In a recombinant *C. glutamicum* variant, a titre of 9 g l⁻¹ salidroside from supplemented tyrosol was achieved by improving UDP-glucose supply and the heterologous expression the glycosyltransferase gene from *Oryza sativa* [84,86] (Table 2). Furthermore, three flavouring phenylbutanoids raspberry ketone, zingerone, and benzylacetone, can be synthesised by supplementing phenylpropanoid precursors using an engineered *C. glutamicum* strain [100]. The key to success was the functional implementation of the curcumin reductase CurA from *Escherichia coli* which possesses unknown benzalacetone reductase activity, required for phenylbutanoid synthesis.

**6-Methylsalicylate, a flavouring agent**

*Corynebacterium glutamicum* was also engineered for the synthesis of 6-methylsalicylate (6-MSA), the methyl ester of salicylic acid found in many plant species, particularly wintergreens [101]. Despite applications as a fragrance or flavouring agent, 6-MSA can also be used in high concentrations as an analgesic and rubefacient to treat joint and muscular pain [102]. The key to the synthesis of 41 mg l⁻¹ 6-MSA from glucose with *C. glutamicum* is the functional expression of 6-MSA synthase ChlB1 from *Streptomyces antibioticus* [103], which is a larger (186 kDa) type I polyketide synthase (Table 2).

**Terpenoids**

Terpenoids comprise carotenoids that are natural yellow- to red-coloured pigments found in plants, fungi, algae, and bacteria [11,71]. They function as light-harvesting photo protectants, membrane stabilisers, and hormone precursors [11]. Chemically, terpenoids consist of isoprene units and are classified according to the length of their carbon backbone [71]. Due to their beneficial effects on humans and in animal health, in particular due to their antioxidative properties, terpenoids are applied as pharmaceuticals and nutraceuticals in the healthcare industry [11,104].
Carotenoids
Most carotenoids contain 40 carbon atoms [105]. The two most prominent representatives are β-carotene, a precursor of pro-vitamin A [105] and astaxanthin, one of the most abundant marine carotenoids and one of the strongest natural antioxidants [106,107]. Naturally, C. glutamicum contains the glycosylated C50 carotenoid decaprenoxanthin as a yellow pigment and, correspondingly, carotenoid biosynthetic genes of the non-mevalonate pathway, involving isopentenyl pyrophosphate as a central intermediate [104]. Native carotenoid biosynthesis is controlled by the GGPP-responsive transcriptional repressor CrtR [108] and is increased via CrtR upon exposure to light [109]. Recent efforts have enabled the production of carotenoids in C. glutamicum with, including the use of lycopene cyclase (crtY) obtained from Pantoea ananatis allowing the production of β-carotene (Table 3). Upon additional heterologous expression of β-caroteneketolase (crtW) from Brevundimonas aurantiaca and hydroxylase (crtZ) (P. ananatis) the recombinant strain produced astaxanthin at a rate of 0.4 mg.l⁻¹ h⁻¹, providing a promising alternative to current algae-based production [106]. Translational fusion of the membrane proteins CrtW with CrtZ improved the production of astaxanthin by 7-fold [107].

Sesquiterpenes
The C15 sesquiterpenes are volatile, which contributes to their use as flavouring agents and fragrances. (+)-Valencene and patchoulol are fragrances present in plant essential oils. Replacement of the endogenous GGPP synthase by E. coli FPP synthase combined with heterologous expression of the plant patchoulol synthase gene from Pogostemon cablin enabled the production of 60 mg.l⁻¹ patchoulol [110] (Table 3). For (+)-valencene production, expression of codon-optimised valencene synthase from the cedar Callitropsis nootkatensis [111] was used instead of patchoulol synthase and upon the use of photocaged IPTG as an optogenetic switch the growth-inhibiting (+)-valencene could be produced to 41 mg.l⁻¹ [112].

Coenzyme Q10
Coenzyme Q10 (CoQ10) serves as an electron carrier in aerobic respiration and exerts antioxidative effects when used as supplements in patients with various diseases. It is an interesting compound. C. glutamicum was the first microbe not natively synthesising CoQ10 that was engineered for CoQ10 production [113] (Table 3). A carotenoid-deficient strain with increased supply of the precursor FPP was constructed to synthesise decaprenyl diposphosphate (DPP) and was the first CoQ10 precursor to express the DPP synthase gene ddsA isolated from Paracoccus denitrificans. Metabolic engineering of the shikimate pathway provided para-hydroxybenzoate (pHBA) as the second CoQ10 precursor. Using ubi genes from E. coli allowed the prenylation of pHBA with DPP followed by decarboxylation, hydroxylation, and methylation reactions to yield CoQ10 [113].

Pyrazines
Pyrazines are monocyclic aromatic rings with two nitrogen atoms, widely used as flavouring agents. C. glutamicum is capable of synthetising these molecules endogenously [114]. Feeding experiments with deuterated acetoin resulted in the incorporation of ²H labelling in tri-methylpyrazine and tetra-methylpyrazine [114]. Together with specifically created C. glutamicum deletion mutants these experiments allowed elucidation of the biosynthetic pathways that produce pyrazines in detail. More recently, heterologous strains of C. glutamicum, which expressed mevalonate kinase from S. aureus and C. kroppenstedtii and 3-hydroxy-3-methylglutaryl-CoA reductase from S. aureus, allowed the synthesis of up to 5 g.l⁻¹ tetra-methylpyrazine [115].

Extremolytes
Extremolytes are small molecules, found in extremophilic bacteria and archaea [68]. They are crucial for adapting their lifestyle to hot, sour, or salty environments due to their protective properties [116,117]. They stabilise and protect macromolecules, membranes, cells, and tissues [118]. Typically, extremolytes are active against different stresses, making them multi-functional agents for the cosmetic, medical, and food industries [116,117]. Chemically, extremolytes comprise a diverse group and include sugars, polyols, heterosides, amino acids, and their derivatives.

The industrial flagship extremolylte small molecule ectoine
Ectoine (S-2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid) is the industrial flagship molecule among extremolytes [119,120]. Discovered in the halophilic bacterium Halorhodospira halochloris [116,117], ectoine has been produced at a scale of several tons per year and achieves prices up to of 1000 US$ kg⁻¹ [121]. Its applications
include the preservation and protection of the skin against cell damage and aging, treatment of atopic dermatitis, lung inflammation, allergic rhinitis, and Alzheimer’s disease, and acts to stabilize proteins, DNA, and RNA [119,120]. Presently, the halophilic microbe Halomonas elongata is used for the industrial production of ectoine. The established ‘bacterial milking’ process is based on intracellular ectoine accumulation in high-salt medium (15% salt), followed by transfer of the cells to a low salinity solution (3% salt), which then promotes ectoine release due to an osmotic down-shock reaction [116]. In addition to the costly industrial process, corrosive damage to conventional stainless steel fermenters and connected devices caused by the salt concentrations have recently stimulated the development of low-salt production strategies [119,120]. Thereby, C. glutamicum has emerged as the world’s best microbial ectoine producer (Table 4). Pioneering studies have engineered the overproduction of ectoine (plus its derivative hydroxyectoine) in a strain of C. glutamicum, which expressed the ectABCD operon from Pseudomonas stutzeri [119], and relied on a biosynthetic involving pathway aspartate semialdehyde as the central precursor. The use of a constitutive promoter decoupled gene expression from its native control by high osmolality [121,122] and the deletion of the lysine exporter abolished l-lysine as a by-product [119]. The tailored strain ECT-2 achieved an ectoine titre of 4.5 g.l⁻¹ from glucose without the use of a high-salinity medium [123]. Subsequently, metabolic engineering of alternative pathways supplied elevated levels of aspartate-semialdehyde, de-repressed glucose metabolism, and abolished lactate secretion [124], which were all beneficial for ectoine formation. The obtained mutant C. glutamicum Ecto-5 achieved an ectoine titre of 22 g.l⁻¹ together with 6 g.l⁻¹ l-lysine as a by-product [124]. More recently, ectoine production could be enhanced even further. For this purpose, the conventional polycistronic operon design was replaced by a monocistronic design to individually control the expression of each of the three genes [119]. A library of 185,193 possible variants of synthetic pathways under randomly distributed expression control was transformed into a chassis strain C. glutamicum, which expressed a feedback resistant aspartokinase to increase supply of aspartate-semialdehyde but lacked the l-lysine exporter to prevent l-lysine secretion. Screening of hundreds of clones finally yielded the strain C. glutamicum ect<sup>opt</sup>, which formed 65 g.l⁻¹ ectoine in a fed-batch process, almost without any by-products [119].

**L-Pipecolic acid, a building block and cell protectant**

L-Pipecolic acid (piperidine 2-carboxylic acid, PA) serves as chiral building block for therapeutic agents [125], and recently its value as a cell-protecting compatible solute has been revealed [126]. Because pipecolic acid is derived from l-lysine, l-lysine overproducers were engineered for l-pipecolic acid production by a synthetic pathway involving oxidative deamination, dehydration, and reduction by l-lysine 6-dehydrogenase (deaminating) from Silicibacter pomeroyi and endogenous pyrroline 5-carboxylate reductase [127] (Table 4). Upon abolishment of the export of the precursor l-lysine and the improvement of expression of the pathway genes, l-pipecolic acid was produced to a titre of 14.4 g.l⁻¹ [128]. The cell-protective properties of l-pipecolic acid as an osmo-protectant could also be demonstrated for the recombinant C. glutamicum strain [126].

**Glucosyl-glycerol, an anti-aging sugar derivative**

Glucosyl-glycerol (glycoin, R-2-O-α-D-glucopyranosyl-glycerol) is naturally produced in marine cyanobacteria and has promising anti-aging activity for use in cosmetics and pharmaceuticals. A recent study described glucosyl-glycerol overproduction in recombinant C. glutamicum [129]. For this purpose, a two-step biosynthetic pathway using the cyanobacterium Synechocystis spp. was introduced. Interestingly, production occurred only in osmotically stressed cells. The elimination of routes to trehalose and glycogen synthesis, competition for ADP-glucose, and endogenous pyrroline 5-carboxylate reductase [127] (Table 4). Upon abolishment of the export of the precursor l-lysine and the improvement of expression of the pathway genes, l-pipecolic acid was produced to a titre of 14.4 g.l⁻¹ [128]. The cell-protective properties of l-pipecolic acid as an osmo-protectant could also be demonstrated for the recombinant C. glutamicum strain [126].

**Hyaluronic acid**

Hyaluronic acid is a naturally occurring polymer. It consists of linear chains of double units of D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine (GlcNAc) with more than 30,000 repeats [130,131] and plays an important role in maintaining structural integrity of cells, tissues, and body fluids [132]. Hyaluronic acid exerts various medical properties. It has been used as a surgical aid in ophthalmology, for joint disease, and wound healing, including skin and cartilage repair [131,133,134]. The market value is estimated at US$10 billion [133]. To overcome the inherent limitations of classical hyaluronic acid extraction from rooster combs and bovine eyes with regards to product safety, reproducibility, and costs [130], significant efforts have been made to develop microbial-based production. The first attempts involved the use of the natural producer Streptococcus bacterium, and provided 7 g.l⁻¹ hyaluronic acid [130] but presented the disadvantage of the potential pathogenicity of the strain [133]. More recently, low levels of
hyaluronic acid production have been established in *E. coli* (3.8 g.l$^{-1}$), *Lactococcus lactis* (1.8 g.l$^{-1}$), and *Bacillus subtilis* (6.8 g.l$^{-1}$) [133,134]. Recently, *C. glutamicum* revealed remarkable hyaluronic acid production capacity. By engineering and evaluation of eight different organisations of the hyaluronic acid operon hasABCDE and further strain optimisation, it was possible to produce 28.7 g.l$^{-1}$ of hyaluronic acid from glucose in a fed-batch fermentation process [133–135].

**Conclusions and outlook**

*C. glutamicum* has emerged as a potent host to produce molecules for human health and well-being, and has greatly expanded its role from a traditional producer of amino acids, chemicals, and materials to a multi-functional microbial production platform. Different success stories have been highlighted in this study, which demonstrate the product capacity of chemically diverse and complex molecules for high-value applications, using entire pathways or synthetic pathway assemblies from various organisms (Tables 1-4). In addition to amino acids, plant (poly)phenols, terpenoids, extremolytes, and medical polymers, have been showcased here. *C. glutamicum* was recently shown to produce antibiotics such as roseoflavin [136], vitamins such as d-pantothenate [137] and vitamin B$_2$ [138], and diagnostic biomarkers for the characterisation of various cancer types such as l-2-hydroxyglutarate [139], N-alkylated amino acids such as N-methyl-l-alanine [140], and N-ethyl-sarcosine [141], as well as chlorinated or brominated l-tryptophans [142,143] for the synthesis of peptide drugs, promising an even wider portfolio in the future. In addition, the functional expression of type I polyketide synthase, renders *C. glutamicum* a promising microbial cell factory to produce type I polyketide synthase-derived high-value molecules. Its valuable native and engineered traits, low nutritional requirements, and capacity for producing chemicals at high titre and yields from second [39] and third generation renewables [144,145], and simultaneous use of sugar mixtures [29], together with a demonstrated robustness [17] ensure the establishment of simple manufacturing processes using *C. glutamicum* all over the world. In the near future, we can expect a further widening of the product portfolio as well as the establishment of next-level cell factories with increased titres, yields, and rates towards an accelerated commercialisation.

**Summary**

- *Corynebacterium glutamicum* is an efficient cell factory for high-value natural products.
- More than 30 accessible compounds have been developed.
- Applications include food, feed, cosmetics, and medical industries.
- Production is enabled by efficient expression of synthetic pathways.

**Competing Interests**
The authors declare that there are no competing interests associated with the manuscript.

**Funding**

Christoph Wittmann received support from the Federal Ministry of Education and Research (BMBF) through the grants from MISSION [031B0611A] and EXTRA [031B0822A] and by the H2020 Bio-based Industries Joint Undertaking through the iFermenter project [790507]. Akihiko Kondo received support from the Ministry of Education, Culture, Sports, Science and Technology (Japan) through the grant JST CREST [JPMJCR13B3] and the Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centers for Advanced Inter-disciplinary Research Areas (Innovative Bioproduction, Kobe). Michael Bott and Jan Marienhagen received support from the BMBF through the “BioökonomieREVIER_INNO” project [031B0918A] and by the Bioeconomy Science Center (BioSC) through the FocusLab project HyImPAct. The scientific activities of the BioSC were financially supported by the Ministry of Innovation, Science and Research of the German State of North Rhine-Westphalia within the framework of the NRW Strategieprojekt BioSC [313/323-400-002 13]. Michael Bott received support from the European Regional Development Fund (ERDF) and the Ministry of Economic Affairs, Innovation, Digitalization and Energy of the German State of North Rhine-Westphalia [34.EFRE-0300097]. Volker F. Wendisch received support from the European Regional Development Fund (ERDF) and the Ministry of Economic Affairs, Innovation, Digitalization and Energy of the German State of North Rhine-Westphalia [EFRE-0300095/1703FI04].
Author Contribution
S.W. and C.W. wrote the first draft of the manuscript. All authors critically commented and approved the manuscript. All authors read and approved the final manuscript.

Abbreviations
4CL, 4-coumaroyl-CoA ligase; DPP, decaprenyl diphosphate; NRPS, non-ribosomal peptide synthetase; pHBA, para-hydroxybenzoate; ROS, reactive oxygen species; STS, stilbene synthase.

References
1 Kinoshita, S., Nakayama, K. and Akita, S. (2014) Taxonomical study of glutamic acid accumulating bacteria Micrococcus glutamicus nov. sp. Bulletin Agricultural Chem. Soc. Japan 22, 176–185
2 Wendisch, V.F. (2020) Metabolic engineering advances and prospects for amino acid production. Metab. Eng. 58, 17–34, https://doi.org/10.1016/j.ymben.2019.03.008
3 Brinkhoff, K., Schröder, J., Pühler, A. and Tauch, A. (2010) The transcriptional regulatory repertoire of Corynebacterium glutamicum: Reconstruction of the network controlling pathways involved in lysine and glutamate production. J. Biotechnol. 149, 173–182, https://doi.org/10.1016/j.jbiotec.2009.12.004
4 Schultz, C., Niebisch, A., Gebel, L. and Bott, M. (2007) Glutamate production by Corynebacterium glutamicum: Dependence on the oxoglutarate dehydrogenase inhibitor protein OdhI and protein kinase PknG. Appl. Microbiol. Biotechnol. 76, 691–700, https://doi.org/10.1007/s00253-007-0933-9
5 Eggeling, L. and Bott, M. (2015) A giant market and a powerful metabolism: L-lysine provided by Corynebacterium glutamicum. Appl. Microbiol. Biotechnol. 99, 3387–3394, https://doi.org/10.1007/s00253-015-6508-2
6 Becker, J., Zelder, O., Häfner, S., Schröder, H. and Wittmann, C. (2011) From zero to hero - Design-based systems metabolic engineering of Corynebacterium glutamicum for L-lysine production. Metab. Eng. 13, 159–168, https://doi.org/10.1016/j.ymben.2011.01.003
7 Kind, S., Becker, J. and Wittmann, C. (2013) Increased lysine production by flux coupling of the tricarboxylic acid cycle and the lysine biosynthetic pathway - Metabolic engineering of the availability of succinyl-CoA in Corynebacterium glutamicum. Metab. Eng. 15, 184–195, https://doi.org/10.1016/j.ymben.2012.07.005
8 Park, S.H., Kim, H.U., Kim, T.Y., Park, J.S., Kim, S.S. and Lee, S.Y. (2014) Metabolic engineering of Corynebacterium glutamicum for L-arginine production. Nat. Commun. 5, 1–9, https://doi.org/10.1038/ncomms6518
9 Bampidis, V., Azimonti, G., de Lourdes Bastos, M., Christensen, H., Dusemund, B., Kouba, M. et al. (2019) Safety and efficacy of L-tryptophan produced by fermentation with Corynebacterium glutamicum KCCM 80176 for all animal species. EFSA J. 17, e05729, https://doi.org/10.2903/j.efsa.2019.5729
10 Becker, J., Rohlies, C.M. and Wittmann, C. (2018) Metabolically engineered Corynebacterium glutamicum for bio-based production of chemicals, fuels, materials, and healthcare products. Metabolic Eng. Commun. 50, 122–141, https://doi.org/10.1016/j.ymetec.2018.07.008
11 Kogure, T. and Inui, M. (2018) Recent advances in metabolic engineering of Corynebacterium glutamicum for bioproduction of value-added aromatic chemicals and natural products. Appl. Microbiol. Biotechnol. 102, 6865–7075, https://doi.org/10.1007/s00253-018-9289-6
12 Siebert, D. and Wendisch, V.F. (2015) Metabolic pathway engineering for production of 1,2-propanediol and 1-propanol by Corynebacterium glutamicum. Biotechnol. Biofuels 8, 1–13, https://doi.org/10.1186/s13068-015-0289-0
13 Tsuge, Y., Hasunuma, T. and Kondo, A. (2015) Recent advances in the metabolic engineering of Corynebacterium glutamicum for the production of lactate and succinate from renewable resources. J. Industrial Microbiol. Biotechnol. 42, 375–389, https://doi.org/10.1007/s10295-014-1538-9
14 Wieschalla, S., Blombach, B., Bott, M. and Eikmanns, B.J. (2013) Bio-based production of organic acids with Corynebacterium glutamicum. Microb. Biotechnol. 6, 87–102, https://doi.org/10.1111/j.1751-7915.2012.12013
15 Litsanov, B., Kabus, A., Brocker, M. and Bott, M. (2012) Efficient aerobic succinate production from glucose in minimal medium with Corynebacterium glutamicum. Microb. Biotechnol. 5, 116–128, https://doi.org/10.1111/j.1751-7915.2011.00310.x
16 Litsanov, B., Brocker, M. and Bott, M. (2012) Toward homosuccinate fermentation: Metabolic engineering of Corynebacterium glutamicum for anaerobic production of succinate from glucose and formate. Appl. Environ. Microbiol. 78, 3325–3337, https://doi.org/10.1128/AEM.07790-11
17 Becker, J., Kuhl, M., Kohlstedt, M., Starck, S. and Wittmann, C. (2018) Metabolic engineering of Corynebacterium glutamicum for the production of cis, cis-muconic acid from lignin. Microbial Cell Factories 17, 1–14, https://doi.org/10.1186/s12934-018-0963-2
18 Kind, S., Jeong, W.K., Schröder, H. and Wittmann, C. (2010) Identification and elimination of the competing N-acetyldiaminopentane pathway for improved production of diaminopentane by Corynebacterium glutamicum. Appl. Environ. Microbiol. 76, 5175–5180, https://doi.org/10.1128/AEM.00834-10
19 Kind, S., Kreys, S. and Wittmann, C. (2011) Metabolic engineering of cellular transport for overproduction of the platform chemical 1,5-diaminopentane in Corynebacterium glutamicum. Metab. Eng. 13, 617–627, https://doi.org/10.1016/j.ymben.2011.07.006
20 Kind, S., Neubauer, S., Becker, J., Yamamoto, M., Volkert, M., von Abendroth, G. et al. (2014) From zero to hero - Production of bio-based nylon from renewable resources using engineered Corynebacterium glutamicum. Metab. Eng. 25, 113–123, https://doi.org/10.1016/j.ymben.2014.05.007
21 Buschke, N., Schröder, H. and Wittmann, C. (2011) Metabolic engineering of Corynebacterium glutamicum for production of 1,5-diaminopentane from hemicellulose. Biotechnol. J. 6, 306–317, https://doi.org/10.1002/biot.201000304
22 Rohles, C.M., Gießelmann, G., Kohlstedt, M., Wittmann, C. and Becker, J. (2016) Systems metabolic engineering of Corynebacterium glutamicum for the production of the carbon-5 platform chemicals 5-aminovalerate and glutarate. Microbial Cell Factories 15, 1–13, https://doi.org/10.1186/s12934-016-0553-0

© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
23 Rohles, C.M., Gläser, L., Kohlstedt, M., Gießelmann, G., Pearson, S., del Campo, A. et al. (2018) A bio-based route to the carbon-5 chemical glutaric acid and to biorylon-6,5 using metabolically engineered Corynebacterium glutamicum. Green Chem. 20, 4662–4674, https://doi.org/10.1039/C8GC01910K

24 Han, T., Kim, G.B. and Lee, S.Y. (2020) Glutaric acid production by systems metabolic engineering of an L-lysine-overproducing Corynebacterium glutamicum. PNAS 117, 30328–30334, https://doi.org/10.1073/pnas.2017483117

25 Peraña-García, F., Jorge, J.M.P., Dreyssas, A., Risse, J.M. and Wendsch, V.F. (2018) Efficient production of the dicarboxylic acid glutarate by Corynebacterium glutamicum via a novel synthetic pathway. Front. Microbiol. 9, 1–13, https://doi.org/10.3389/fmicb.2018.02589

26 Kawaguchi, H., Sasaki, K., Uematsu, K., Tsuge, Y., Teramura, H., Okai, N. et al. (2015) 3-Amino-4-hydroxybenzoic acid production from sweet sorghum juice by recombinant Corynebacterium glutamicum. Bioresour. Technol. 198, 410–417, https://doi.org/10.1016/j.biortech.2015.09.024

27 Becker, J. and Wittmann, C. (2012) Bio-based production of chemicals, materials and fuels - Corynebacterium glutamicum as versatile cell factory. Curr. Opin. Biotechnol. 23, 631–640, https://doi.org/10.1016/j.copbio.2011.11.012

28 Blombach, B. and Seibold, G.M. (2010) Carbohydrate metabolism in Corynebacterium glutamicum and applications for the metabolic engineering of L-lysine production strains. Appl. Microbiol. Biotechnol. 86, 1313–1322, https://doi.org/10.1007/s00253-010-1573-z

29 Kawaguchi, H., Yoshihara, K., Hara, K.Y., Hasunuma, T., Ogino, C. and Kondo, A. (2018) Metabolome analysis-based design and engineering of a metabolic pathway in Corynebacterium glutamicum to match rates of simultaneous utilization of D-glucose and L-arabinose. Microbial Cell Factories 17, 1–16, https://doi.org/10.1186/s12934-018-0927-6

30 Becker, J. and Wittmann, C. (2015) Advanced biotechnology: Metabolically engineered cells for the bio-production of chemicals and fuels, materials, and health-care products. Angew. Chem. 54, 3328–3350, https://doi.org/10.1002/anie.201409033

31 Lee, J.Y., Na, Y.A., Kim, E., Lee, H.S. and Kim, P. (2016) The actinobacterium Corynebacterium glutamicum, an industrial workhorse. J. Microbiol. Biotechnol. 26, 807–822, https://doi.org/10.4014/jmb.1601.01053

32 Bayan, N., Houssin, C., Chami, M. and Leblon, G. (2003) Mycomembrane and S-layer: two important structures of pathogenic Corynebacterium glutamicum. Front. Microbiol. 104, 55–67, https://doi.org/10.1002/0022-1656(2003)00163-9

33 Vertes, A.A., Inui, M. and Yukawa, H. (2012) Postgenomic approaches to using corynebacteria as biocatalysts. Annu. Rev. Microbiol. 66, 521–550, https://doi.org/10.1146/annurev-micro-010312-105506

34 Puech, V., Chami, M., Lemassou, A., Laneelle, M.-A., Schiffler, B., Gounon, P. et al. (2001) Structure of the cell envelope of corynebacteria: Importance of the noncovalently bound lipids in the formation of the cell wall permeability barrier and fracture plane. Microbiology 147, 1365–1382, https://doi.org/10.1099/00221287-147-5-1365

35 Kohlstedt, M., Sappa, P.K., Meyer, H., Maafi, S., Zaprasii, A., Hoffmann, T. et al. (2014) Adaptation of Bacillus subtilis carbon core metabolism to simultaneous nutrient limitation and osmotic challenge: A multi-omics perspective. Environ. Microbiol. 16, 1896–1917, https://doi.org/10.1111/1462-2920.12438

36 Becker, J. and Wittmann, C. (2018) From systems biology to metabolically engineered cells - an omics perspective on the development of industrial microbes. Curr. Opin. Microbiol. 45, 180–188, https://doi.org/10.1016/j.mib.2018.06.001

37 Krömer, J.O., Sorgenfrei, O., Klopprogge, K., Heinzle, E. and Wittmann, C. (2004) Combined analysis of the transcriptome, metabolome, and fluxome. J. Biotechnol. 105, 534–540, https://doi.org/10.1016/j.biot.2003.10.024

38 Wendisch, V.F., Bott, M., Kalinowski, J., Oldiges, M. and Wiechert, W. (2006) Emerging Corynebacterium glutamicum systems biology. J. Biotechnol. 124, 74–92, https://doi.org/10.1016/j.jbiotec.2005.12.002

39 Buschke, N., Becker, J., Schäfer, R., Kiefer, P., Biedendieck, R. and Wittmann, C. (2013) Systems metabolic engineering of xylose-utilizing Corynebacterium glutamicum for production of 1,5-diaminopentane. Biotechnol. J. 8, 557–570, https://doi.org/10.1002/biot.201200367

40 Rezola, A., de Figureiredo, L.F., Brock, M., Pey, J., Podhorski, A., Wittmann, C. et al. (2011) Exploring metabolic pathways in genome-scale networks via generating flux modes. Bioinformatics 27, 534–540, https://doi.org/10.1093/bioinformatics/btp681

41 Krömer, J.O., Wittmann, C., Schröder, H. and Heinzle, E. (2006) Metabolic pathway analysis for rational design of L-methionine production by Escherichia coli and Corynebacterium glutamicum. Metab. Eng. 8, 353–369, https://doi.org/10.1016/j.mib.2006.02.001

42 Metzer, G., Esfandabadi, M.E., Franco-Lara, E. and Wittmann, C. (2009) Flux design: In silico design of cell factories based on correlation of pathway fluxes to desired properties. BMC Syst. Biol. 3, 1–16, https://doi.org/10.1186/1752-0509-3-120

43 Kirchner, O. and Tauch, A. (2003) Tools for genetic engineering in the amino acid-producing bacterium Corynebacterium glutamicum. J. Biotechnol. 104, 287–299, https://doi.org/10.1016/S0168-1656(03)00148-2

44 Nesvera, J. and Patek, M. (2011) Tools for genetic manipulations in Corynebacterium glutamicum and their applications. Appl. Microbiol. Biotechnol. 90, 1641–1654, https://doi.org/10.1007/s00253-011-3272-9

45 Vertes, D.A., Inui, M. and Yukawa, H. (2005) Manipulating corynebacteria, from individual genes to chromosomes. Appl. Environ. Microbiol. 71, 7633–7642, https://doi.org/10.1128/AEM.71.12.7633-7642.2005

46 Henke, N.A., Krah, I. and Wendisch, V.F. (2021) Improved plasmid-based inducible and constitutive gene expression in Corynebacterium glutamicum. Microorganisms 9, 1–15, https://doi.org/10.3390/microorganisms9010204

47 Bakkes, P.J., Ramp, P., Bida, A., Dohmen-Olima, D., Bott, M. and Freudl, R. (2020) Improved pKEK2-derived expression vectors for tightly controlled production of recombinant proteins in Corynebacterium glutamicum. Plasmid 112, https://doi.org/10.1016/j.plasmid.2020.102540

48 Becker, J., Buschke, N., Bükker, R. and Wittmann, C. (2010) Systems level engineering of Corynebacterium glutamicum - Reprogramming translational efficiency for superior production. Eng. Life Sci. 10, 430–438, https://doi.org/10.1002/elsc.201000008

49 Baumgart, M., Unthan, S., Kloß, R., Radek, A., Polen, T., Tenhaef, N. et al. (2018) Corynebacterium glutamicum Chassis C1*: Building and testing a novel platform host for synthetic biology and industrial biotechnology. ACS Synthetic Biol. 7, 132–144, https://doi.org/10.1021/acssynbio.7b00261
50. Hemerich, J., Labib, M., Steffens, C., Reich, S.J., Weiske, M., Baumgart, M. et al. (2020) Screening of a genome-reduced Corynebacterium glutamicum strain library for improved heterologous cutinase secretion. *Microb. Biotechnol.* **13**, 2020–2031, https://doi.org/10.1111/1751-7913.13660

51. Binder, S., Schendzielorz, G., Stäbler, N., Krumbach, K., Hoffmann, K., Bott, M. et al. (2012) A high-throughput approach to identify genomic variants of bacterial metabolite producers at the single-cell level. *Genome Biol.* **13**, 1–12, https://doi.org/10.1186/gb-2012-13-5-r40

52. Della Corte, D., van Beek, H.L., Syberg, F., Schalimney, M., Tobola, F., Cormann, K.U. et al. (2020) Engineering and application of a biosensor with focused ligand specificity. *Nat. Commun.* **11**, 1–11, https://doi.org/10.1038/s41467-020-18400-0

53. Mahr, R., Gätgens, C., Gätgens, J., Polen, T., Kalinowski, J. and Fruenzke, J. (2015) Biosensor-driven adaptive laboratory evolution of L-valine production in *Corynebacterium glutamicum*. *Metabolic Eng. Commun.* **32**, 184–194, https://doi.org/10.1016/j.mebc.2015.09.017

54. Oide, S., Gunji, W., Moteki, Y., Yamamoto, S., Suda, M., Jojima, T. et al. (2015) Thermal and solvent stress cross-tolerance conferred to *Corynebacterium glutamicum* by adaptive laboratory evolution. *Appl. Environ. Microbiol.* **81**, 2284–2296, https://doi.org/10.1128/AEM.03973-14

55. Vassilev, I., Gießelmann, G., Schwechheimer, S.K., Wittmann, C., Virdis, B. and Krömer, J.O. (2018) Anodic electro-fermentation: Anaerobic production of L-lysine by recombinant *Corynebacterium glutamicum*. *Biotechnol. Bioeng.* **115**, 1499–1508, https://doi.org/10.1002/bit.26562

56. Wang, X., Zhang, H. and Quinn, P.J. (2018) Production of L-valine from metabolically engineered *Corynebacterium glutamicum*. *Appl. Microbiol. Biotechnol.* **102**, 4319–4330, https://doi.org/10.1007/s00253-018-8952-2

57. Sanchez, S., Rodriguez-Sanoja, R., Ramos, A. and Demain, A.L. (2017) Our microbes not only produce antibiotics, they also overproduce amino acids. *J. Antimicrob. Chemother.* **71**, 26–36, https://doi.org/10.1093/jac/dkx074

58. Bolten, C.J., Schröder, H., Dickschat, J. and Wittmann, C. (2010) Towards methionine overproduction in *Corynebacterium glutamicum* - Methanethiol and dimethylsulfoxide as reduced sulfur sources. *J. Microbiol. Biotechnol.* **20**, 1196–1203, https://doi.org/10.4104/jm.2010.02018

59. Oldiges, M., Eikmanns, B.J. and Blombach, B. (2014) Application of metabolic engineering for the biotechnological production of L-valine. *Appl. Microbiol. Biotechnol.* **98**, 5859–5870, https://doi.org/10.1007/s00253-014-5782-8

60. Zhang, H., Li, Y., Wang, C. and Wang, X. (2018) Understanding the high l-valine production in *Corynebacterium glutamicum* WB-1 using transcriptomics and proteomics. *Sci. Rep.* **8**, 1–18, https://doi.org/10.1038/s41598-018-21926-5

61. Menken, A., Wolters, H.J. and Honikel, K.O. (2005) Amino acid production in *Corynebacterium glutamicum* by the PucR-type transcriptional regulator GabR and by alternative nitrogen and carbon sources. *African J. Biotechnol.* **4**, 1028–1036, https://doi.org/10.7754/AJB.2005.4.6.1028

62. Vogt, M., Haas, S., Klaft, S., Polen, T., Eggeling, L., van Ooyen, J. et al. (2014) Pushing product formation to its limit: Metabolic engineering of *Corynebacterium glutamicum* for L-leucine overproduction. *Metab. Eng.* **22**, 40–52, https://doi.org/10.1016/j.ymben.2013.12.001

63. Zhang, H., Li, Y. and Wang, X. (2018) Metabolic engineering of L-valine synthesis and secretory pathways in *Corynebacterium glutamicum* for higher production. *Chin. J. Biotechnol.* **34**, 1606–1619, https://doi.org/10.13345/j.cjb.180112

64. Wendisch, V.F. (2015) Engineering microbial cell factories: Metabolic engineering of *Corynebacterium glutamicum* with a focus on non-natural products. *Biotechnol. J.* **10**, 1170–1184, https://doi.org/10.1002/biot.201400590

65. Takahashi, C., Shirakawa, J., Tsuchida, T., Okai, N., Hatada, K., Nakayama, H. et al. (2012) Robust production of gamma-amino butyric acid using recombinant *Corynebacterium glutamicum* expressing glutamate decarboxylase from *Escherichia coli*. *Enzyme Microb. Technol.* **51**, 171–176, https://doi.org/10.1016/j.enzmictec.2012.05.010

66. Tanaka, Y. and Sato, K. (2002) Screening for high-yield producers of gamma-amino GABA. *Appl. Microbiol. Biotechnol.* **60**, 284–289, https://doi.org/10.1007/s00253-001-1422-6

67. Heider, S.A. and Wendisch, V.F. (2015) Engineering microbial cell factories: Metabolic engineering of *Corynebacterium glutamicum* with a focus on non-natural products. *Biotechnol. J.* **10**, 1170–1184, https://doi.org/10.1002/biot.201400590

68. Zhu, L., Mack, C., Wirtz, A., Kranz, A., Polen, T., Baumgart, M. et al. (2020) Regulation of gamma-amino butyrate (GABA) utilization in *Corynebacterium glutamicum* by the PucR-type transcriptional regulator GabB and by alternative nitrogen and carbon sources. *Front. Microbiol.* **11**, https://doi.org/10.3389/fmicb.2020.544045

69. Zhao, Z., Ding, J.Y., Ma, W.H., Zhou, N.Y. and Liu, S.J. (2012) Identification and characterization of γ-amino butyric acid uptake system GabP<sub>3</sub> (NcGbp<sub>0464</sub>) in *Corynebacterium glutamicum*. *Appl. Environ. Microbiol.* **78**, 2596–2601, https://doi.org/10.1128/AEM.07406-11

70. Chol, J.W., Yim, S.S., Lee, S.H., Kang, T.J., Park, S.J. and Jeong, K.J. (2015) Enhanced production of gamma-aminobutyrate (GABA) in recombinant *Corynebacterium glutamicum* by expressing glutamate decarboxylase active in expanded pH range. *Microbial Cell Factories* **14**, 1–11, https://doi.org/10.1186/s12934-015-0205-9
